Point72 Asia Singapore Pte. Ltd. Has $311,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

Point72 Asia Singapore Pte. Ltd. lowered its stake in Arcus Biosciences, Inc. (NYSE:RCUS) by 23.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,347 shares of the company’s stock after selling 6,330 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Arcus Biosciences were worth $311,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RCUS. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Arcus Biosciences by 8.7% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 744,298 shares of the company’s stock valued at $11,336,000 after acquiring an additional 59,273 shares during the last quarter. SG Americas Securities LLC increased its holdings in Arcus Biosciences by 1,396.1% in the 2nd quarter. SG Americas Securities LLC now owns 129,292 shares of the company’s stock worth $1,969,000 after purchasing an additional 120,650 shares in the last quarter. GSA Capital Partners LLP raised its position in Arcus Biosciences by 17.8% in the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock valued at $2,866,000 after purchasing an additional 28,307 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Arcus Biosciences in the 2nd quarter valued at approximately $1,286,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Arcus Biosciences by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,858 shares of the company’s stock worth $455,000 after acquiring an additional 2,123 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Stock Up 3.5 %

Arcus Biosciences stock opened at $16.49 on Wednesday. The company has a market capitalization of $1.51 billion, a PE ratio of -5.23 and a beta of 0.88. Arcus Biosciences, Inc. has a 12-month low of $13.52 and a 12-month high of $20.31. The firm’s fifty day moving average is $16.25 and its 200 day moving average is $16.01. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.06. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company had revenue of $48.00 million for the quarter, compared to analysts’ expectations of $38.95 million. During the same quarter in the prior year, the firm earned ($0.94) EPS. The business’s revenue was up 50.0% on a year-over-year basis. As a group, sell-side analysts predict that Arcus Biosciences, Inc. will post -3.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on RCUS. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a report on Thursday, November 7th. Evercore ISI raised shares of Arcus Biosciences to a “strong-buy” rating in a research report on Friday, August 9th. HC Wainwright restated a “neutral” rating and issued a $20.00 price target on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Barclays upped their price objective on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Finally, Wells Fargo & Company started coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They set an “overweight” rating and a $29.00 target price for the company. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $34.00.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.